1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20(1):133-63.
2. Prasad R, Kapoor K. Multidrug resistance in yeast Candida. Int Rev Cytol. 2005; 242:215-48.
3. Saibabu V, Fatima Z, Khan LA, Hameed S. Therapeutic potential of dietary phenolic acids. Adv Pharmacol Sci. 2015; 2015:1-10.
4. World Health Organization. Summary of evaluations performed by the joint FAO/WHO expert committee on food additives. Hamilton, Ontario, CN: Canadian Centre for Occupational Health and Safety; 2004.
5. Fleck CB, Schöbel F, Brock M. Nutrient acquisition by pathogenic fungi: nutrient availability, pathway regulation, and differences in substrate utilization. Int J Med Microbiol. 2011; 301(5):400-7.
6. Van Schaik EJ, Tom M, Woods DE. Burkholderia pseudomallei isocitrate lyase is a persistence factor in pulmonary melioidosis: implications for the development of isocitrate lyase inhibitors as novel antimicrobials. Infect Immun. 2009; 77(10):4275-83.
7. Ebel F, Schwienbacher M, Beyer J, Heesemann J, Brakhage AA, Brock M. Analysis of the regulation, expression, and localisation of the isocitrate lyase from Aspergillus fumigatus, a potential target for antifungal drug development. Fungal Genet Biol. 2006; 43(7):476-89.
8. Krátký M, Vinšová J. Advances in mycobacterial isocitrate lyase targeting and inhibitors. Curr Med Chem. 2013; 19(36):6126-37.
9. Lorenz MC, Fink GR. Life and death in a macrophage: role of the glyoxylate cycle in virulence. Eukaryotic Cell. 2002; 1(5):57-62.
10. Lorenz MC, Fink GR. The glyoxylate cycle is required for fungal virulence. Nature. 2001; 412(6842):83-6.
11. Ansari MA, Fatima Z, Ahmad K, Hameed S. Monoterpenoid perillyl alcohol impairs metabolic flexibility of Candida albicans by inhibiting glyoxylate cycle. Biochem Biophys Res Commun. 2018; 495(1):560-6.
12. Webb W, Sali A. Protein structure modeling with MODELLER. Methods Mol Biol. 2017; 1654:39-54.
13. Wu S, Skolnick J, Zhang Y. Ab initio modeling of small proteins by iterative TASSER simulations. BMC Biol. 2007; 5:17.
14. Ahmad K, Bhat AR, Athar F. Pharmacokinetic evaluation of callistemon viminalis derived natural compounds as targeted inhibitors against δ-opioid receptor and farnesyl transferase. Lett Drug Design Discovery. 2017; 14(4):488-99.
15. Saibabu V, Fatima Z, Ahmad K, Khan LA, Hameed S. Octyl gallate triggers dysfunctional mitochondria leading to ROS driven membrane damage and metabolic inflexibility along with attenuated virulence in Candida albicans. Med Mycol. 2019; 28:54.
16. Ebel F, Schwienbacher M, Beyer J, Heesemann J, Brakhage AA, Brock M. Analysis of the regulation, expression, and localisation of the isocitrate lyase from Aspergillus fumigatus, a potential target for antifungal drug development. Fungal Genet Biol. 2006; 43(7):476-89.
17. Berman J, Sudbery PE. Candida albicans: a molecular revolution built on lessons from budding yeast. Nat Rev Genet. 2002; 3(12):918-30.
18. Singulani JL, Scorzoni L, Gomes PC, Nazaré AC, Polaquini CR, Regasini LO, Fusco-Almeida AMMendes-Giannini MJSet al. Activity of gallic acid and its ester derivatives in Caenorhabditis elegans and zebrafish (Danio rerio) models. Future Med Chem. 2017; 9(16):1863-72.
19. Okoli I, Coleman JJ, Tampakakis E, An WF, Holson E, Wagner F, et al. Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One. 2009; 4(9):e7025.
20. Manoharan RK, Lee JH, Kim YG, Kim SI, Lee J. Inhibitory effects of the essential oils alphalongipinene and linalool on biofilm formation and hyphal growth of Candida albicans. Biofouling. 2017; 33(2):143-55.